|
🐜
|
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
30 auth.
A. Sartore-Bianchi,
L. Trusolino,
C. Martino,
K. Bencardino,
S. Lonardi,
F. Bergamo,
V. Zagonel,
F. Leone,
Ilaria Depetris,
E. Martinelli,
T. Troiani,
F. Ciardiello,
P. Racca,
A. Bertotti,
G. Siravegna,
...
V. Torri,
A. Amatu,
S. Ghezzi,
G. Marrapese,
L. Palmeri,
E. Valtorta,
A. Cassingena,
C. Lauricella,
A. Vanzulli,
D. Regge,
S. Veronese,
P. Comoglio,
A. Bardelli,
S. Marsoni,
S. Siena
|
9 |
2016 |
9
🐜
|
|
🐜
|
Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study.
20 auth.
M. Goetz,
M. Callstrom,
J. Charboneau,
M. Farrell,
T. Maus,
T. Welch,
G. Y. Wong,
J. Sloan,
P. Novotny,
I. Petersen,
...
R. Beres,
D. Regge,
R. Capanna,
M. Saker,
D. Grönemeyer,
A. Gevargez,
K. Ahrar,
M. Choti,
T. de Baère,
J. Rubin
|
9 |
2004 |
9
🐜
|
|
🐜
|
Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study).
12 auth.
R. Lencioni,
L. Crocetti,
R. Cioni,
R. Suh,
D. Glenn,
D. Regge,
...
T. Helmberger,
A. Gillams,
A. Frilling,
M. Ambrogi,
C. Bartolozzi,
A. Mussi
|
9 |
2008 |
9
🐜
|
|
🐜
|
Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer.
12 auth.
F. Porpiglia,
M. Manfredi,
F. Mele,
M. Cossu,
E. Bollito,
A. Veltri,
...
S. Cirillo,
D. Regge,
R. Faletti,
R. Passera,
C. Fiori,
S. De Luca
|
7 |
2017 |
7
🐜
|
|
🐜
|
Monitoring Response to Primary Chemotherapy in Breast Cancer using Dynamic Contrast-enhanced Magnetic Resonance Imaging
12 auth.
L. Martincich,
F. Montemurro,
G. De Rosa,
V. Marra,
R. Ponzone,
S. Cirillo,
...
M. Gatti,
N. Biglia,
I. Sarotto,
P. Sismondi,
D. Regge,
M. Aglietta
|
7 |
2004 |
7
🐜
|
|
🐜
|
Postoperative Liver Dysfunction and Future Remnant Liver: Where Is the Limit?
7 auth.
A. Ferrero,
L. Viganó,
R. Polastri,
A. Muratore,
Haris Eminefendic,
D. Regge,
...
L. Capussotti
|
7 |
2007 |
7
🐜
|
|
🐜
|
Correlations between diffusion-weighted imaging and breast cancer biomarkers
12 auth.
L. Martincich,
V. Deantoni,
I. Bertotto,
S. Redana,
Franziska Kubatzki,
I. Sarotto,
...
V. Rossi,
M. Liotti,
R. Ponzone,
M. Aglietta,
D. Regge,
F. Montemurro
|
7 |
2012 |
7
🐜
|
|
🐢
|
Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging
9 auth.
S. Cirillo,
M. Petracchini,
L. Scotti,
T. Gallo,
A. Macera,
M. Bona,
...
C. Ortega,
P. Gabriele,
D. Regge
|
7 |
2009 |
7
🐢
|
|
🐜
|
Portal vein ligation as an efficient method of increasing the future liver remnant volume in the surgical treatment of colorectal metastases.
7 auth.
L. Capussotti,
A. Muratore,
F. Baracchi,
B. Lelong,
A. Ferrero,
D. Regge,
...
J. Delpero
|
7 |
2008 |
7
🐜
|
|
🐜
|
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
25 auth.
A. Sartore-Bianchi,
F. Pietrantonio,
S. Lonardi,
Benedetta Mussolin,
F. Rua,
G. Crisafulli,
A. Bartolini,
E. Fenocchio,
A. Amatu,
P. Manca,
F. Bergamo,
F. Tosi,
G. Mauri,
M. Ambrosini,
F. Daniel,
...
V. Torri,
A. Vanzulli,
D. Regge,
G. Cappello,
C. Marchiò,
E. Berrino,
A. Sapino,
S. Marsoni,
S. Siena,
A. Bardelli
|
7 |
2022 |
7
🐜
|
|
🐜
|
The second ESGAR consensus statement on CT colonography
9 auth.
E. Neri,
S. Halligan,
M. Hellström,
P. Lefere,
T. Mang,
D. Regge,
...
J. Stoker,
S. Taylor,
A. Laghi
|
7 |
2012 |
7
🐜
|
